Mostrar el registro sencillo del ítem

dc.contributor.author
Hoppu, Kalle  
dc.contributor.author
Anabwani, Gabriel  
dc.contributor.author
Garcia Bournissen, Facundo  
dc.contributor.author
Gazarian, Madlen  
dc.contributor.author
Kearns, Gregory L.  
dc.contributor.author
Nakamura, Hidefumi  
dc.contributor.author
Peterson, Robert G.  
dc.contributor.author
Sri Ranganathan, Shalini  
dc.contributor.author
De Wildt, Saskia N.  
dc.date.available
2023-03-30T13:32:41Z  
dc.date.issued
2011-07  
dc.identifier.citation
Hoppu, Kalle; Anabwani, Gabriel; Garcia Bournissen, Facundo; Gazarian, Madlen; Kearns, Gregory L.; et al.; The status of paediatric medicines initiatives around the world-what has happened and what has not?; Springer; European Journal Of Clinical Pharmacology; 68; 1; 7-2011; 1-10  
dc.identifier.issn
0031-6970  
dc.identifier.uri
http://hdl.handle.net/11336/192128  
dc.description.abstract
Purpose: This review was conducted to examine the current status of paediatric medicines initiatives across the globe. Methods: The authors made a non-systematic descriptive review of current world situation. Results: Two regions, the United States (US) and the European Union (EU), and the World Health Organization (WHO) have introduced strong paediatric initiatives to improve children's health through improving access to better paediatric medicines. The experience from the US initiative indicates that it is possible to stimulate development and study of paediatric medicines and provide important new information for improvement of paediatric therapy. The early results from the EU initiative are similarly encouraging. In Canada, Japan, Australia and other developed countries, specific paediatric medicines initiatives have been less extensive and weaker, with modest results. Disappointingly, current evidence suggests that results from clinical trials outside the US often do not benefit children in the country in which the trials were largely conducted. Pharmaceutical companies that have derived a financial benefit commensurate with the cost of doing the paediatric trials in one country do not seem to be making the results of these trials available to all countries if there is no financial incentive to the company. The WHO campaign 'make medicines child size' has produced substantive accomplishments in building improved foundations to improve mechanisms that will enhance children's access to critical medicines in resource-limited settings. However, practically all of this work has been performed using an amalgamation of short-term funding from a variety of sources as opposed to a sustained, programmatic commitment. Conclusions: Although much still needs to be done, it's clear that with concerted efforts and appropriate resources, change is possible but slow. Retaining and fostering public and political interest in paediatric medicines is challenging, but pivotal for success.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
BIOMEDICAL RESEARCH  
dc.subject
CHILD  
dc.subject
DRUGS, INVESTIGATIONAL  
dc.subject
JURISPRUDENCE  
dc.subject
LEGISLATION  
dc.subject.classification
Farmacología y Farmacia  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
The status of paediatric medicines initiatives around the world-what has happened and what has not?  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-03-29T17:19:52Z  
dc.journal.volume
68  
dc.journal.number
1  
dc.journal.pagination
1-10  
dc.journal.pais
Alemania  
dc.journal.ciudad
Berlin  
dc.description.fil
Fil: Hoppu, Kalle. Helsinki University Central Hospital; Finlandia  
dc.description.fil
Fil: Anabwani, Gabriel. Botswana-Baylor Children’s Clinical Centre of Excellence; Botsuana  
dc.description.fil
Fil: Garcia Bournissen, Facundo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; Argentina  
dc.description.fil
Fil: Gazarian, Madlen. University of New South Wales; Australia. Sydney Children’s Hospital; Australia  
dc.description.fil
Fil: Kearns, Gregory L.. The Children’s Mercy Hospital; Estados Unidos. University of Missouri; Estados Unidos  
dc.description.fil
Fil: Nakamura, Hidefumi. National Center for Child Health and Development; Japón  
dc.description.fil
Fil: Peterson, Robert G.. University of British Columbia; Canadá  
dc.description.fil
Fil: Sri Ranganathan, Shalini. University Of Colombo. Faculty Of Medicine; Sri Lanka  
dc.description.fil
Fil: De Wildt, Saskia N.. Sophia Children’s Hospital; Países Bajos  
dc.journal.title
European Journal Of Clinical Pharmacology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00228-011-1089-1  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s00228-011-1089-1